TY - JOUR
T1 - Novel treatments for chronic hepatitis C
T2 - closing the remaining gaps
AU - Alkhouri, Naim
AU - Lawitz, Eric
AU - Poordad, Fred
PY - 2017/12
Y1 - 2017/12
N2 - Direct acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection with cure rates >90% for the majority of patients and excellent safety profile. However, there remain certain unmet needs in treating HCV including treatment for patients that failed a prior DAA regimen and for those with advanced chronic kidney disease. In addition, shortening the duration of DAA regimens has the potential to increase compliance and decrease the cost of care. New regimens that were approved by the FDA in 2017 address these unmet needs and will be discussed in this concise review.
AB - Direct acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection with cure rates >90% for the majority of patients and excellent safety profile. However, there remain certain unmet needs in treating HCV including treatment for patients that failed a prior DAA regimen and for those with advanced chronic kidney disease. In addition, shortening the duration of DAA regimens has the potential to increase compliance and decrease the cost of care. New regimens that were approved by the FDA in 2017 address these unmet needs and will be discussed in this concise review.
UR - http://www.scopus.com/inward/record.url?scp=85032941032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032941032&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2017.10.001
DO - 10.1016/j.coph.2017.10.001
M3 - Review article
C2 - 29121533
AN - SCOPUS:85032941032
SN - 1471-4892
VL - 37
SP - 107
EP - 111
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
ER -